0001104659-26-026140
SEC filingSagimet Biosciences Inc. reported a net loss of $51.0 million for fiscal year 2025, driven by total operating expenses of $56.9 million, which consisted of $39.1 million in research and development expenses and $17.8 million in general and administrative expenses. The company's loss from operations was $56.9 million, partially offset by other income of $5.9 million, primarily from interest income. The net loss per share was $2.00 for both basic and diluted calculations, based on weighted-average shares outstanding of 32.3 million. The company's total comprehensive loss was $51.1 million, which includes a net unrealized loss on marketable securities of $110,000. On the balance sheet, total assets stood at $116.5 million, with current assets of $116.4 million including cash and cash equivalents of $35.0 million and short-term marketable securities of $78.1 million. Total liabilities were $5.1 million, resulting in stockholders' equity of $111.4 million. Cash flow from operations was negative $45.6 million, while investing activities provided $4.6 million and financing activities contributed $275,000, leading to a net decrease in cash of $40.8 million.
Sagimet Biosciences Inc. reported a net loss of $51.0 million for fiscal year 2025, with no revenue reported in the financial statements. The company's loss from operations was $56.9 million, driven by total operating expenses of $56.9 million. Research and development expenses accounted for $39.1 million of the total operating expenses, while general and administrative expenses were $17.8 million. Other income of $5.9 million, primarily from interest income, partially offset the operating loss. The net loss per share was $2.00 for both basic and diluted calculations, based on weighted-average shares outstanding of 32.3 million. Total comprehensive loss was $51.1 million, which includes a net unrealized loss on marketable securities of $110,000.
No revenue was reported for Sagimet Biosciences Inc. in the fiscal year 2025 financial statements. The company appears to be in a pre-revenue stage of development, with no segment breakdown, geographic mix, or revenue growth drivers disclosed in the provided financial data. All financial results reflect operating expenses and losses without corresponding revenue generation.
As a pre-revenue company, Sagimet Biosciences reported negative operating income of $56.9 million and negative net income of $51.0 million for fiscal year 2025. The company's cost structure is dominated by research and development expenses of $39.1 million, which represents approximately 69% of total operating expenses. General and administrative expenses of $17.8 million account for the remaining 31% of operating costs. The company's financial performance reflects its investment in research and development activities without corresponding revenue generation.
Net cash used in operating activities was $45.6 million for fiscal year 2025, primarily driven by the net loss of $51.0 million, adjusted for non-cash items including stock-based compensation expense of $6.4 million. Investing activities provided $4.6 million in net cash, resulting from $111.4 million in sales and maturities of marketable securities offset by $106.9 million in purchases. Financing activities contributed $275,000 from the exercise of stock options. The net decrease in cash and cash equivalents was $40.8 million. The balance sheet shows total assets of $116.5 million, with current assets of $116.4 million including cash and cash equivalents of $35.0 million and short-term marketable securities of $78.1 million. Total liabilities were $5.1 million, resulting in stockholders' equity of $111.4 million.
No specific management guidance, strategic priorities, or forward-looking statements were provided in the financial data presented. The company's financial statements reflect a pre-revenue stage of development with significant investment in research and development activities. The balance sheet indicates liquidity with $35.0 million in cash and cash equivalents and $78.1 million in short-term marketable securities as of December 31, 2025. The company's ability to continue operations will depend on its ability to raise additional capital and advance its research and development programs.